SCHEMBL1068007

SCHEMBL1068007

COC(=O)/C=C(\CBr)Oc1cccc(OC)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.40
HPGDS O60760 1/20 0.37
NFE2L2 Q16236 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KAT6A Q92794 1/20 0.36
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 1/20 0.35
CA12 O43570 2/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
P2RX7 Q99572 1/20 0.35
NPC1 O15118 2/20 0.35
POLB P06746 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1068011 1.00 KMT2A (0.40) KMT2AHPGDSNFE2L2SMN1; SMN2KAT6A
SCHEMBL1068009 1.00 KMT2A (0.40) KMT2AHPGDSNFE2L2SMN1; SMN2KAT6A
SCHEMBL1068468 0.80 KMT2A (0.43) KMT2ANFE2L2SMN1; SMN2KAT6AKDM4E
SCHEMBL1068472 0.80 KMT2A (0.43) KMT2ANFE2L2SMN1; SMN2KAT6AKDM4E
SCHEMBL1068470 0.80 KMT2A (0.43) KMT2ANFE2L2SMN1; SMN2KAT6AKDM4E
SCHEMBL1066758 0.79 KMT2A (0.46) KMT2ASMN1; SMN2KDM4EMEN1CA12
SCHEMBL1066755 0.79 KMT2A (0.46) KMT2ASMN1; SMN2KDM4EMEN1CA12
SCHEMBL1067380 0.78 GLA (0.35) KMT2ASMN1; SMN2KDM4EMEN1NPC1
SCHEMBL1067374 0.78 GLA (0.35) KMT2ASMN1; SMN2KDM4EMEN1NPC1
SCHEMBL1067378 0.78 GLA (0.35) KMT2ASMN1; SMN2KDM4EMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 KMT2A 2072/4885HPGDS 614/4885NFE2L2 852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.